RxDoctor Payments Data

Kimberly Huhn, PA

Physician Assistant · East Lansing, MINPI 1649472523

Payments from drug & device makers

$9,280in general payments, 2019–2025

Across 583 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Pfizer$897
  • Amgen$708
  • AstraZeneca$665
  • Lilly USA, LLC$505
  • plus $4K from 50 others

What the payments were for

  • Food & beverage$9,280100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,280 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$1,993
Medicare patients
20
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$136,295
JardianceEmpagliflozin67$106,681
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$71,032
EliquisApixaban41$62,591
TrulicityDulaglutide14$34,488
MounjaroTirzepatide23$31,941
MyrbetriqMirabegron33$30,785
XareltoRivaroxaban25$28,189
FarxigaDapagliflozin Propanediol18$23,596
Tresiba Flextouch U-200Insulin Degludec13$19,068
VraylarCariprazine Hcl11$18,040
Breo ElliptaFluticasone/Vilanterol18$9,110
RestasisCyclosporine13$7,041
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$6,561
Aripiprazole41$5,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,319$136,29584 claims
Boehringer IngelheimJardiance$195$106,68167 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$302$84,93983 claims
Lilly USA, LLCTrulicity, Mounjaro$505$66,42837 claims
PfizerEliquis$897$62,59141 claims
Johnson & JohnsonXarelto$85$28,18925 claims
AbbVieVraylar, Restasis, Synthroid$1,411$26,63440 claims
AstraZenecaFarxiga$665$23,59618 claims
MerckBelsomra$148$5,50113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in East Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →